Inhalable dry powders of rifampicin highlighting potential and drawbacks in formulation development for experimental tuberculosis aerosol therapy

• Published in: Expert opinion on drug delivery Vol. 17; no. 3; p. 305
• Main Authors: Berkenfeld, Kai, McConville, Jason T, Lamprecht, Alf
• Format: Journal Article
• Language: English
• Published: England 03.03.2020
• Subjects: Administration, Inhalation; Aerosols; Biological Availability; Dry Powder Inhalers; Excipients - chemistry; Humans; Lung - microbiology; Powders; Rifampin - administration & dosage; Tuberculosis - drug therapy; inhalable therapy; NGI; rifampicin; Tuberculosis; DPI; aerosol testing
• ISSN: 1744-7593
• DOI: 10.1080/17425247.2020.1720644

: Recently, tuberculosis was reported as the leading cause of death from a single infectious agent. Standard therapy includes administration of four first-line antibiotics, i.e. rifampicin, isoniazid, ethambutol, and pyrazinamide over a period of at least 26 weeks, which in case of rifampicin oftentimes is accompanied by unwanted side effects and variable bioavailability that compromise a positive therapeutic outcome. As the main site of infection is the lungs, it is desirable to develop a therapeutic formulation to be administered via the pulmonary route. : This work presents a literature review on studies investigating inhalable dry powder formulations including rifampicin in the context of an experimental tuberculosis therapy, with a special focus on aerosol performance. : It was found that formulation approaches involving different strategies and functional excipients are under investigation but as of now, no formulation has managed to leap into commercial clinical testing. Reasons for this might not primarily be associated with a lack of suitable candidates, but amongst others a lack of suitable models to assess the efficacy, therapeutic benefit, and cost-effectiveness of the candidate formulations.